GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm ...

The pharma giant will pay $1.2 billion up-front for efimosfermin, with the deal including potential success-based milestone ...

GSK will buy efimosfermin, a specialty medicine used to treat liver disease from Boston Pharmaceuticals, for up to $2 billion ...

GSK has already moved on from its decision to drop a cancer asset on Tuesday by snagging a late-stage liver disease candidate ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.

In recent years, the U.K.-listed pharma giant has called increasingly on U.S. law firms for its transactional work.

GSK Plc and iTeos Therapeutics ended the development of an experimental lung cancer drug, the latest in a series of setbacks ...

GSK plc with its development partner iTeos Therapeutics, Inc., has announced that it is ending the development programme for ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...

LONDON] GSK agreed to buy an experimental medicine to treat liver disease for as much as US$2 billion as the UK drugmaker ...